Completed OBSERVATIONAL NCT05096143
A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data
Sponsor: Novartis Pharmaceuticals
Conditions
Heart Failure
Interventions
ACEi/ARB Sacubitril/valsartan
Updated 4 times since 2021 Last updated: Dec 15, 2021 Started: Jun 3, 2020 Primary completion: Oct 19, 2020 Completion: Oct 19, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A observational or N/A phase clinical study on Heart Failure, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 4 data snapshots since 2020. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2022 — Jul 2024 [monthly]
Completed
-
Nov 2021 — Jan 2022 [monthly]
Completed
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Novartis Pharmaceuticals
Data source: Novartis
For direct contact, visit the study record on ClinicalTrials.gov .